Kyverna Net Income Per Share from 2010 to 2026

KYTX Stock   8.36  0.36  4.13%   
Kyverna Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2026. During the period from 2010 to 2026, Kyverna Therapeutics Net Loss regression line of annual values had significance of  0.01 and arithmetic mean of (1.43). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(3.82)
Current Value
(3.63)
Quarterly Volatility
1.06192453
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Kyverna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kyverna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 18.4 M, Interest Income of 18.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 136, Dividend Yield of 0.0 or PTB Ratio of 0.46. Kyverna financial statements analysis is a perfect complement when working with Kyverna Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Kyverna Stock
Check out the analysis of Kyverna Therapeutics Correlation against competitors.

Latest Kyverna Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Kyverna Therapeutics Common over the last few years. It is Kyverna Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kyverna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Kyverna Net Income Per Share Regression Statistics

Arithmetic Mean(1.43)
Coefficient Of Variation(74.48)
Mean Deviation0.76
Median(1.02)
Standard Deviation1.06
Sample Variance1.13
Range3.7304
R-Value(0.58)
Mean Square Error0.79
R-Squared0.34
Significance0.01
Slope(0.12)
Total Sum of Squares18.04

Kyverna Net Income Per Share History

2026 -3.63
2025 -3.82
2024 -3.33
2023 -0.0896
2022 -1.12

About Kyverna Therapeutics Financial Statements

Kyverna Therapeutics investors use historical fundamental indicators, such as Kyverna Therapeutics' Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kyverna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(3.82)(3.63)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kyverna Stock Analysis

When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.